Myriad Genetics, Inc. MYGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 202.70M | 190.70M | 200.40M | 209.80M | 205.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 202.70M | 190.70M | 200.40M | 209.80M | 205.70M |
| Cost of Revenue | 65.00M | 63.70M | 62.80M | 63.00M | 61.90M |
| Gross Profit | 137.70M | 127.00M | 137.60M | 146.80M | 143.80M |
| SG&A Expenses | 151.10M | 140.90M | 135.80M | 124.30M | 138.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 242.60M | 229.60M | 225.70M | 212.80M | 229.00M |
| Operating Income | -39.90M | -38.90M | -25.30M | -3.00M | -23.30M |
| Income Before Tax | -43.60M | -42.60M | -34.10M | -8.90M | -26.20M |
| Income Tax Expenses | 300.00K | 600.00K | -- | -1.00M | 1.20M |
| Earnings from Continuing Operations | -43.90M | -43.20M | -34.10M | -7.90M | -27.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.90M | -43.20M | -34.10M | -7.90M | -27.40M |
| EBIT | -39.90M | -38.90M | -25.30M | -3.00M | -23.30M |
| EBITDA | -27.30M | -26.40M | -12.80M | 9.60M | -10.70M |
| EPS Basic | -0.46 | -0.46 | -0.36 | -0.08 | -0.29 |
| Normalized Basic EPS | -0.28 | -0.28 | -0.19 | -0.04 | -0.18 |
| EPS Diluted | -0.46 | -0.46 | -0.36 | -0.08 | -0.29 |
| Normalized Diluted EPS | -0.28 | -0.28 | -0.19 | -0.04 | -0.18 |
| Average Basic Shares Outstanding | 95.70M | 94.80M | 93.70M | 93.30M | 93.10M |
| Average Diluted Shares Outstanding | 95.70M | 94.80M | 93.70M | 93.30M | 93.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |